

## Special Issue

# Advances in Cancer Biology and Experimental Anticancer Therapies

### Message from the Guest Editors

Cancer rates are on the rise. Among the various barriers to tumor treatment, the phenomenon of multidrug resistance (MDR) is a major obstacle limiting the effectiveness of the administered chemo drugs. Therefore, it is essential to intensify studies on the molecular mechanisms of carcinogenesis and develop novel tactics to predict, diagnose, and fight tumors. Currently, selective kinase inhibitors, micro-RNAs, nano-based theranostic tools, and combinatory approaches are considered the most promising strategies. This issue aims to provide an update on the currently investigated molecular factors promoting the progression of cancer and antitumor therapeutic strategies.

### Guest Editors

Dr. Damian Gawel

1. Centre of Postgraduate Medical Education, Department of Immunohematology, Marymoncka 99/103, 01-813 Warsaw, Poland
2. Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, Marymoncka 99/103, 01-813 Warsaw, Poland

Dr. Tiziana Vavalà

AOU Città della Salute e della Scienza, Torino, Italy

### Deadline for manuscript submissions

closed (30 April 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/109563](https://mdpi.com/si/109563)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).